S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

PHASE3TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Pancreatic NeoplasmNeoplasm Metastasis
Interventions
DRUG

S-1

oral administration

DRUG

5-Fluorouracil

intravenous bolus

Trial Locations (17)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, San José

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Mixco

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Ocean Business Plaza

Sanofi-Aventis Administrative Office, Lima

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Mégrine

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00602745 - S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen | Biotech Hunter | Biotech Hunter